REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K

What Happened
Reviva Pharmaceuticals Holdings, Inc. announced on May 13, 2026 that it issued a press release disclosing financial information and operating metrics for the fiscal quarter ended March 31, 2026 and discussing its business outlook. The company filed a Form 8-K (Item 2.02) to report these quarterly results and attached the press release as Exhibit 99.1.

Key Details

• Press release date: May 13, 2026; covers the fiscal quarter ended March 31, 2026.
• The 8-K was filed under Item 2.02 (Results of Operations and Financial Condition) and references the press release for detailed figures and commentary.
• Exhibit 99.1 to the 8-K contains the press release with the disclosed financials and operating metrics.
• The filing states the press release also discusses the company's business outlook.

Why It Matters
This 8-K signals that Reviva has publicly disclosed its latest quarterly performance and outlook—material information investors use to assess revenue, profitability, cash position, and operational trends. Retail investors should review the attached press release (Exhibit 99.1) for the specific numbers (revenue, net income/loss, cash metrics, and any guidance) before making investment decisions, since the Form 8-K itself references that release as the source of the financial details.